CLDX Celldex Therapeutics Inc.

2.89
+0.03  (1%)
Previous Close 2.86
Open 2.86
Price To book 1.80
Market Cap 392997601
Shares 135,985,329
Volume 177,720
Short Ratio 4.92
Av. Daily Volume 1,514,983

SEC filingsSee all SEC filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 171191271
  2. 8-K - Current report 171191226
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171181190
  4. 8-K - Current report 171181157
  5. 8-K - Current report 171116116

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiation announced November 18, 2017.
CDX-3379
Recurrent/metastatic head and neck squamous cell cancer
Phase 1/2 initiated July 2016. Phase 1 enrollment ongoing.
CDX-014
Renal cell carcinoma (RCC) - cancer
Phase 2 initiated April 2016. Enrollment to be completed 1Q 2018.
Varlilumab and nivolumab
Solid tumors - cancer
Noted March 14, 2017 that development will not be advanced to Phase 2
Varlilumab and atezolizumab (anti-PDL1)
Renal cell carcinoma (RCC) cancer
Noted March 14, 2017 that development will not be advanced to Phase 2
Varlilumab and sunitinib (Sutent)
Clear cell renal cell carcinoma (CC-RCC) cancer
Phase 1/2 commenced April 2016.
Glembatumumab vedotin
Squamous cell lung cancer
Trial discontinued early March 2016 as unlikely to meet primary endpoint
CDX-110 rindopepimut - ACT IV
Cancer- glioblastoma multiforme (GBM) front line
Phase 2b completion of enrollment announced August 23, 2017. Data 2Q 2018.
Glembatumumab vedotin
Metastatic triple negative breast cancers that overexpress gpNMB
Phase 2 continues to enroll. Glembatumumab vedotin and varlilumab arm data released at SITC November 2017.
Glembatumumab vedotin, varlilumab, Opdivo or Keytruda
Cancer - melanoma

Latest News

  1. ETFs with exposure to Celldex Therapeutics, Inc. : November 20, 2017
  2. Celldex (CLDX) Initiates Phase II Study on Cancer Candidate
  3. Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma
  4. Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
  5. Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : November 9, 2017
  6. How to Invest in Biotech Stocks
  7. Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up
  8. Today's Research Reports on Trending Tickers: Celldex Therapeutics and Idera Pharmaceuticals
  9. How Much Did Celldex Therapeutics Inc’s (CLDX) CEO Pocket Last Year?
  10. Why Celldex Therapeutics Jumped Higher Today
  11. Celldex Therapeutics, Inc.'s Most Important Takeaway From Q3 Isn't a Number
  12. Why Celldex Therapeutics Stock Crumbled in October
  13. Celldex reports 3Q loss
  14. Celldex Reports Third Quarter 2017 Results
  15. Is Celldex Therapeutics Inc (CLDX) Undervalued?
  16. Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?
  17. Celldex Therapeutics, Inc. – Value Analysis (NASDAQ:CLDX) : October 26, 2017
  18. Celldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CLDX-US : October 25, 2017
  19. Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics

SEC Filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 171191271
  2. 8-K - Current report 171191226
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171181190
  4. 8-K - Current report 171181157
  5. 8-K - Current report 171116116
  6. 8-K - Current report 171081164
  7. S-8 - Securities to be offered to employees in employee benefit plans 171021494
  8. S-8 - Securities to be offered to employees in employee benefit plans 171021455
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014745
  10. 8-K - Current report 171014632